Business

Statement regarding Hikma Pharmaceuticals Plc

Brookfield Private Capital (DIFC) Limited has issued a statement confirming it does not intend to make an offer for Hikma Pharmaceuticals Plc, in accordance with Rule 2.8 of the UK City Code on Takeovers and Mergers. This announcement means Brookfield and any concert parties are restricted from making a further offer for Hikma for six months, unless specific conditions are met, such as the agreement of Hikma's board or the announcement of a competing offer from a third party. Disclaimer*

articleHikma Pharmaceuticals PlcFebruary 4, 20265/company/hikma-pharmaceuticals-plc/news/statement-regarding-hikma-pharmaceuticals-plc
Statement regarding Hikma Pharmaceuticals Plc

About this update from Hikma Pharmaceuticals Plc

[{"type":"text","content":"\n\n \nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.\n \nTHIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE UK CITY CODE ON TAKEOVERS AND MERGERS (THE \"CODE\").\n \n \nFOR IMMEDIATE RELEASE\n \n4 February 2026\n \nStatement regarding Hikma Pharmaceuticals Plc (\"Hikma\")\n \nBrookfield Private Capital (DIFC) Limited, acting for and on behalf of funds managed and/or advised by its affiliates (\"Brookfield\") notes the recent press speculation and confirms that it does not intend to make an offer for Hikma.\n \nThis announcement is made by Brookfield in accordance with Rule 2.8 of the Code. As a result of this announcement Brookfield (and any person acting in concert with it) will, except with the consent of the UK Panel on Takeovers and Mergers (the \"Panel\"), be bound by the restrictions contained in Rule 2.8 of the Code.\n \nUnder Note 2 on Rule 2.8 of the Code, Brookfield reserves the right to set aside the restrictions in Rule 2.8 in the following circumstances: (i) with the agreement of the board of Hikma; (ii) if a third party announces a firm intention to make an offer for Hikma; (iii) if Hikma announces a Rule 9 waiver proposal (see Note 1 of the Notes on Dispensations from Rule 9) or a reverse takeover (as defined in the Code); or (iv) if there has been a material change of circumstances (as determined by the Panel).\n \nEnquiries:\n \nBrookfield\nMarie Fuller                                                                                                       +44 (0) 20 4557 4334\n \nImportant information\n \nThis announcement is not intended to, and does not, constitute, represe...

More updates from Hikma Pharmaceuticals Plc